Abstract
AbstractG‐quadruplexes (G4s) have been revived as promising therapeutic targets with the development of immunotherapy, but the G4‐mediated immune response remains unclear. We designed a novel class of G4‐binding organic‐platinum hybrids, L1‐cispt and L1‐transpt, with spatial matching for G4 binding and G4 DNA reactivity for binding site locking. The solution structure of L1‐transpt‐MYT1L G4 demonstrated the effectiveness of the covalent binding and revealed the covalent binding‐guided dynamic balance, accompanied by the destruction of the A5‐T17 base pairs to achieve the covalent binding of the platinum unit to N7 of the G6 residue. Furthermore, L1‐cispt‐ and L1‐transpt‐mediated genomic dysfunction could activate the retinoic acid‐induced gene I (RIG‐I) pathway and induce immunogenic cell death (ICD). The use of L1‐cispt/L1‐transpt‐treated dying cells as therapeutic vaccines stimulated a robust immune response and effectively inhibited tumor growth in vivo. Our findings highlight the importance of the rational combination of specific spatial recognition and covalent locking in G4‐trageting drug design and their potential in immunotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.